Conmed (CNMD) Net Income towards Common Stockholders (2010 - 2026)

Conmed (CNMD) has 17 years of Net Income towards Common Stockholders data on file, last reported at $23.1 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders rose 7.7% year-over-year to $23.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $56.5 million (down 48.73% YoY) and the FY2025 annual result came in at $47.1 million, down 64.47% from the prior year.
• Net Income towards Common Stockholders climbed to $23.1 million in Q2 2026, from $13.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $49.0 million in Q3 2024 to a low of -$168.3 million in Q2 2022.
• A 5-year average of $11.1 million and a median of $18.2 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 1366.3% — and 2024, when it surged 983.51%.
• Tracing CNMD's Net Income towards Common Stockholders over 5 years: stood at $26.6 million in 2022, then advanced by 24.4% to $33.1 million in 2023, then advanced by 2.07% to $33.8 million in 2024, then slumped by 50.41% to $16.7 million in 2025, then jumped by 37.83% to $23.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $23.1 million (Q2 2026), $13.8 million (Q1 2026), and $16.7 million (Q4 2025), per Business Quant data.